{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:43:38Z","timestamp":1768736618701,"version":"3.49.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The study was conducted to investigate the effects of hydroxychloroquine, an\nanti-inflammatory drug, which was recently approved and used as an add on oral antidiabetic drug\nfor uncontrolled Type 2 Diabetes Mellitus (DM) on an adequate dose of sulfonylurea and metformin\non the progression of diabetic retinopathy (DR) in subjects with Rheumatoid Arthritis and\nType 2 Diabetes Mellitus. The primary objective was to evaluate the effect of hydroxychloroquine\non the onset of Diabetic Retinopathy (DR) and progression of the disease. Best-corrected visual\nacuity (BCVA) charts with 3 or more lines worsening of visual acuity and the development of clinically\nsignificant macular edema (CSME) were added as secondary objectives as described in the\nEarly Treatment Diabetic Retinopathy Study (ETDRS).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This retrospective analysis was done from medical records of all Rheumatoid Arthritis\n(RA) patients who also had T2DM and were treated with hydroxychloroquine (HCQ) 400 mg OD\nor 200 mg BID (N=65) and received ophthalmologic care at an endocrinology clinic in India up to\na mean follow-up of 3.5\u00b10.5 years and matched subjects taking any other disease-modifying antirheumatic\ndrugs (DMARD) and pioglitazone (N=34).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Baseline characteristics were similar in both the groups, with matched glycated haemoglobin\n(9.1 % and 9.2 % respectively, p=0.127). In both groups, over 3.5 years, HbA1c was reduced\nsignificantly. No new cases of DR were detected in the HCQ group, whereas 2 patients had\ndeveloped DR in the pioglitazone group. At the base line visit, mild non-proliferative Diabetic\nRetinopathy (NPDR) was present in 18 eyes and 14 eyes in the HCQ and pioglitazone groups, respectively.\nProgression to moderate NPDR over 3.5 years occurred in 2 out of 18 (11 %) eyes in\nthe HCQ group and 8 out of 14 (57 %) eyes in the pioglitazone group, respectively, representing a\nsignificant relative risk reduction (p=.001). No patients had progressed from mild NDPR to severe\nNPDR in the HCQ group, whereas 2 eyes had progressed from mild NPDR to severe NPDR in the\npioglitazone group. None of the patients in either arm developed diabetic macular oedema.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Progression of DR from mild to moderate NPDR or severe NPDR may be delayed by\nHCQ. Large scale randomised prospective clinical trial is required to establish the risk-benefit profiles\nof HCQ in T2DM.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399818666220118101320","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:07:50Z","timestamp":1642565270000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in\nSubjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus"],"prefix":"10.2174","volume":"18","author":[{"given":"Arjun","family":"Baidya","sequence":"first","affiliation":[{"name":"Department of Endocrinology, NRS Medical College and Hospital, Kolkata, WB, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399818666220118101320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200322\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399818666220118101320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T13:06:09Z","timestamp":1655903169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200322\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399818666220118101320","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e180122200322"}}